Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
Deal Would Include Hikma Acquiring GSK’s 91.2% Holding
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
You may also be interested in...
HBW Insight reveals the biggest consumer health deals of 2020, and identifies growing private equity investment, portfolio streamlining by major players and pharma firms exiting OTC as the major drivers of M&A activity.
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.
COVID-19 has not held back GSK's preparations to create the world's largest standalone consumer health business, with CEO Emma Walmsley confirming separation is on track for summer next year.